Analysts Set MediWound Ltd. (NASDAQ:MDWD) PT at $31.25

Shares of MediWound Ltd. (NASDAQ:MDWD) have been assigned a consensus recommendation of “Buy” from the five analysts that are covering the firm, MarketBeat.com reports. Five research analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokerages that have covered the stock in the last year is $31.80.

A number of equities analysts have issued reports on the stock. Wall Street Zen raised shares of MediWound to a “sell” rating in a report on Friday, March 21st. Alliance Global Partners initiated coverage on shares of MediWound in a research report on Friday, May 2nd. They set a “buy” rating and a $25.00 price target on the stock. Oppenheimer initiated coverage on shares of MediWound in a research report on Monday. They issued an “outperform” rating and a $34.00 price objective for the company. HC Wainwright set a $31.00 price objective on shares of MediWound and gave the company a “buy” rating in a research note on Thursday, May 22nd. Finally, Craig Hallum assumed coverage on MediWound in a research note on Friday, February 28th. They issued a “buy” rating and a $39.00 target price on the stock.

Institutional Investors Weigh In On MediWound

A number of large investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC increased its stake in shares of MediWound by 1,507.1% in the first quarter. GAMMA Investing LLC now owns 1,816 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 1,703 shares during the period. R Squared Ltd bought a new stake in shares of MediWound during the fourth quarter valued at approximately $32,000. Russell Investments Group Ltd. grew its stake in MediWound by 154.1% in the fourth quarter. Russell Investments Group Ltd. now owns 1,916 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 1,162 shares during the period. Corebridge Financial Inc. raised its holdings in MediWound by 17.1% in the first quarter. Corebridge Financial Inc. now owns 4,559 shares of the biopharmaceutical company’s stock worth $71,000 after purchasing an additional 665 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in MediWound by 22.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock valued at $85,000 after buying an additional 999 shares during the period. Hedge funds and other institutional investors own 46.83% of the company’s stock.

MediWound Trading Up 0.5%

MDWD stock opened at $21.70 on Monday. The stock has a 50-day moving average price of $18.21 and a 200-day moving average price of $17.87. MediWound has a 1-year low of $12.78 and a 1-year high of $24.00. The firm has a market cap of $234.53 million, a PE ratio of -7.48 and a beta of 0.30.

MediWound (NASDAQ:MDWD) last issued its earnings results on Wednesday, May 21st. The biopharmaceutical company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.58. The business had revenue of $3.96 million during the quarter, compared to analyst estimates of $5.20 million. MediWound had a negative return on equity of 82.17% and a negative net margin of 142.29%. During the same period in the previous year, the company posted ($1.05) EPS. On average, analysts forecast that MediWound will post -2.66 earnings per share for the current year.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.